| Followers | 8 |
| Posts | 2087 |
| Boards Moderated | 0 |
| Alias Born | 07/31/2006 |
Tuesday, June 01, 2010 10:01:03 AM
Exactly! "Significant" in this usage means statistically significant. It means the study concluded that the observed efficacy was the result of the experimental treatment with a confidence of 95% or even 99% (depending on the stastical threshold employed).
Said another way, the use of the word "significant" means the scientists concluded that the chance of the observed positive findings being due to random chance as opposed to being the direct result of the expeimental treatment (the "nano", as our friend would improperly say) are only 5% or 1%.
This is better than quoting just the raw numbers. This is a scientific characterization of the raw numbers, and is the only thing that's important. These ARE the results, and they are very good. Having the actual raw numbers would add nothing to anyone's understanding of the outcome of this study, given that we already have the statistical characterization.
Drs. Harris and Seymour, having used the words "significant efficacy" in the press release, have put their professional reputations on the line. The good doctors certainly would not commit career suicide by using these words carelessly or inappropriately.
Any spin coming today from those few vocal ditractors, trying to say "where are the results" or "they must not be good or they would have published them", simply would be an attempt to push a lie in an effort to scare people and talk down the share price, and/or would demonstrate their total lack of understanding of the process of scientific testing.
best to all.
Said another way, the use of the word "significant" means the scientists concluded that the chance of the observed positive findings being due to random chance as opposed to being the direct result of the expeimental treatment (the "nano", as our friend would improperly say) are only 5% or 1%.
This is better than quoting just the raw numbers. This is a scientific characterization of the raw numbers, and is the only thing that's important. These ARE the results, and they are very good. Having the actual raw numbers would add nothing to anyone's understanding of the outcome of this study, given that we already have the statistical characterization.
Drs. Harris and Seymour, having used the words "significant efficacy" in the press release, have put their professional reputations on the line. The good doctors certainly would not commit career suicide by using these words carelessly or inappropriately.
Any spin coming today from those few vocal ditractors, trying to say "where are the results" or "they must not be good or they would have published them", simply would be an attempt to push a lie in an effort to scare people and talk down the share price, and/or would demonstrate their total lack of understanding of the process of scientific testing.
best to all.
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
